ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000139

Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients

Identifieur interne : 000139 ( PascalFrancis/Corpus ); précédent : 000138; suivant : 000140

Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients

Auteurs : Shauna Brady ; Paul Lalli ; Nisha Midha ; Ayechen Chan ; Alexandra Garven ; Cynthia Chan ; Cory Toth

Source :

Chemical senses [ 0379-864X ] ; 2013.

RBID : Francis:13-0217482

Descripteurs français

Pascal (Inist)
- Névralgie, Douleur neuropathique, Performance, Olfaction, Diabète de type 2, Neuropathie, Homme.

English descriptors

KwdEn :
- Human, Neuralgia, Neuropathic pain, Neuropathy, Olfaction, Performance, Type 2 diabetes.

Abstract

Olfactory dysfunction in neurodegenerative conditions such as Parkinson's syndrome and Alzheimer's disease can hallmark disease onset. We hypothesized that patients with diabetes mellitus, a condition featuring peripheral and central neurodegeneration, would have decreased olfaction abilities. We examined participants with diabetic peripheral neuropathy, participants with diabetes without diabetic peripheral neuropathy, and control participants in blinded fashion using standardized Sniffin' Sticks. Diabetic peripheral neuropathy severity was quantified using the Utah Early Neuropathy Scale. Further subcategorization of diabetic peripheral neuropathy based on presence of neuropathic pain was performed with Douleur Neuropathique 4 Questionnaires. Participants with diabetes had decreased olfactory sensitivity, impaired olfactory discrimination abilities, and reduced odor identification skills when compared with controls. However, loss of olfaction ability was, at least partially, attributed to presence of neuropathic pain on subcategory assessment, although pain severity was not associated with dysfunction. Those participants with diabetes without diabetic peripheral neuropathy and those with diabetic peripheral neuropathy without neuropathic pain had similar olfactory function as controls in general. The presence of neuropathic pain, associated with limited attention and concentration, may explain at least a portion of the olfactory dysfunction witnessed in the diabetic patient population.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0379-864X`
A02	`01`			`@0 CHSED8`
A03		`1`		`@0 Chem. senses`
A05				`@2 38`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients`
A11	`01`	`1`		`@1 BRADY (Shauna)`
A11	`02`	`1`		`@1 LALLI (Paul)`
A11	`03`	`1`		`@1 MIDHA (Nisha)`
A11	`04`	`1`		`@1 CHAN (Ayechen)`
A11	`05`	`1`		`@1 GARVEN (Alexandra)`
A11	`06`	`1`		`@1 CHAN (Cynthia)`
A11	`07`	`1`		`@1 TOTH (Cory)`
A14	`01`			`@1 Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary @2 Calgary, AB @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A20				`@1 497-507`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16455 @5 354000503830910040`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/4`
A47	`01`	`1`		`@0 13-0217482`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Chemical senses`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Olfactory dysfunction in neurodegenerative conditions such as Parkinson's syndrome and Alzheimer's disease can hallmark disease onset. We hypothesized that patients with diabetes mellitus, a condition featuring peripheral and central neurodegeneration, would have decreased olfaction abilities. We examined participants with diabetic peripheral neuropathy, participants with diabetes without diabetic peripheral neuropathy, and control participants in blinded fashion using standardized Sniffin' Sticks. Diabetic peripheral neuropathy severity was quantified using the Utah Early Neuropathy Scale. Further subcategorization of diabetic peripheral neuropathy based on presence of neuropathic pain was performed with Douleur Neuropathique 4 Questionnaires. Participants with diabetes had decreased olfactory sensitivity, impaired olfactory discrimination abilities, and reduced odor identification skills when compared with controls. However, loss of olfaction ability was, at least partially, attributed to presence of neuropathic pain on subcategory assessment, although pain severity was not associated with dysfunction. Those participants with diabetes without diabetic peripheral neuropathy and those with diabetic peripheral neuropathy without neuropathic pain had similar olfactory function as controls in general. The presence of neuropathic pain, associated with limited attention and concentration, may explain at least a portion of the olfactory dysfunction witnessed in the diabetic patient population.
C02	`01`	`X`		`@0 770B05F @1 II`
C03	`01`	`X`	`FRE`	`@0 Névralgie @5 01`
C03	`01`	`X`	`ENG`	`@0 Neuralgia @5 01`
C03	`01`	`X`	`SPA`	`@0 Neuralgia @5 01`
C03	`02`	`X`	`FRE`	`@0 Douleur neuropathique @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Neuropathic pain @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Dolor neuropática @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Performance @5 03`
C03	`03`	`X`	`ENG`	`@0 Performance @5 03`
C03	`03`	`X`	`SPA`	`@0 Rendimiento @5 03`
C03	`04`	`X`	`FRE`	`@0 Olfaction @5 04`
C03	`04`	`X`	`ENG`	`@0 Olfaction @5 04`
C03	`04`	`X`	`SPA`	`@0 Olfación @5 04`
C03	`05`	`X`	`FRE`	`@0 Diabète de type 2 @2 NM @5 05`
C03	`05`	`X`	`ENG`	`@0 Type 2 diabetes @2 NM @5 05`
C03	`05`	`X`	`SPA`	`@0 Diabetes de tipo 2 @2 NM @5 05`
C03	`06`	`X`	`FRE`	`@0 Neuropathie @5 06`
C03	`06`	`X`	`ENG`	`@0 Neuropathy @5 06`
C03	`06`	`X`	`SPA`	`@0 Neuropatía @5 06`
C03	`07`	`X`	`FRE`	`@0 Homme @5 18`
C03	`07`	`X`	`ENG`	`@0 Human @5 18`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 18`
C07	`01`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Trouble neurologique @5 38`
C07	`02`	`X`	`ENG`	`@0 Neurological disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Trastorno neurológico @5 38`
C07	`03`	`X`	`FRE`	`@0 Perception @5 39`
C07	`03`	`X`	`ENG`	`@0 Perception @5 39`
C07	`03`	`X`	`SPA`	`@0 Percepción @5 39`
C07	`04`	`X`	`FRE`	`@0 Endocrinopathie @5 40`
C07	`04`	`X`	`ENG`	`@0 Endocrinopathy @5 40`
C07	`04`	`X`	`SPA`	`@0 Endocrinopatía @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie métabolique @5 41`
C07	`05`	`X`	`ENG`	`@0 Metabolic diseases @5 41`
C07	`05`	`X`	`SPA`	`@0 Metabolismo patología @5 41`
N21				`@1 203`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	FRANCIS 13-0217482 INIST
ET :	Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients
AU :	BRADY (Shauna); LALLI (Paul); MIDHA (Nisha); CHAN (Ayechen); GARVEN (Alexandra); CHAN (Cynthia); TOTH (Cory)
AF :	Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary/Calgary, AB/Canada (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Chemical senses; ISSN 0379-864X; Coden CHSED8; Royaume-Uni; Da. 2013; Vol. 38; No. 6; Pp. 497-507; Bibl. 1 p.1/4
LA :	Anglais
EA :	Olfactory dysfunction in neurodegenerative conditions such as Parkinson's syndrome and Alzheimer's disease can hallmark disease onset. We hypothesized that patients with diabetes mellitus, a condition featuring peripheral and central neurodegeneration, would have decreased olfaction abilities. We examined participants with diabetic peripheral neuropathy, participants with diabetes without diabetic peripheral neuropathy, and control participants in blinded fashion using standardized Sniffin' Sticks. Diabetic peripheral neuropathy severity was quantified using the Utah Early Neuropathy Scale. Further subcategorization of diabetic peripheral neuropathy based on presence of neuropathic pain was performed with Douleur Neuropathique 4 Questionnaires. Participants with diabetes had decreased olfactory sensitivity, impaired olfactory discrimination abilities, and reduced odor identification skills when compared with controls. However, loss of olfaction ability was, at least partially, attributed to presence of neuropathic pain on subcategory assessment, although pain severity was not associated with dysfunction. Those participants with diabetes without diabetic peripheral neuropathy and those with diabetic peripheral neuropathy without neuropathic pain had similar olfactory function as controls in general. The presence of neuropathic pain, associated with limited attention and concentration, may explain at least a portion of the olfactory dysfunction witnessed in the diabetic patient population.
CC :	770B05F
FD :	Névralgie; Douleur neuropathique; Performance; Olfaction; Diabète de type 2; Neuropathie; Homme
FG :	Pathologie du système nerveux; Trouble neurologique; Perception; Endocrinopathie; Maladie métabolique
ED :	Neuralgia; Neuropathic pain; Performance; Olfaction; Type 2 diabetes; Neuropathy; Human
EG :	Nervous system diseases; Neurological disorder; Perception; Endocrinopathy; Metabolic diseases
SD :	Neuralgia; Dolor neuropática; Rendimiento; Olfación; Diabetes de tipo 2; Neuropatía; Hombre
LO :	INIST-16455.354000503830910040
ID :	13-0217482

Links to Exploration step

Francis:13-0217482

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients</title>
<author><name sortKey="Brady, Shauna" sort="Brady, Shauna" uniqKey="Brady S" first="Shauna" last="Brady">Shauna Brady</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lalli, Paul" sort="Lalli, Paul" uniqKey="Lalli P" first="Paul" last="Lalli">Paul Lalli</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Midha, Nisha" sort="Midha, Nisha" uniqKey="Midha N" first="Nisha" last="Midha">Nisha Midha</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Ayechen" sort="Chan, Ayechen" uniqKey="Chan A" first="Ayechen" last="Chan">Ayechen Chan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garven, Alexandra" sort="Garven, Alexandra" uniqKey="Garven A" first="Alexandra" last="Garven">Alexandra Garven</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Cynthia" sort="Chan, Cynthia" uniqKey="Chan C" first="Cynthia" last="Chan">Cynthia Chan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Toth, Cory" sort="Toth, Cory" uniqKey="Toth C" first="Cory" last="Toth">Cory Toth</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0217482</idno>
<date when="2013">2013</date>
<idno type="stanalyst">FRANCIS 13-0217482 INIST</idno>
<idno type="RBID">Francis:13-0217482</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000139</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients</title>
<author><name sortKey="Brady, Shauna" sort="Brady, Shauna" uniqKey="Brady S" first="Shauna" last="Brady">Shauna Brady</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lalli, Paul" sort="Lalli, Paul" uniqKey="Lalli P" first="Paul" last="Lalli">Paul Lalli</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Midha, Nisha" sort="Midha, Nisha" uniqKey="Midha N" first="Nisha" last="Midha">Nisha Midha</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Ayechen" sort="Chan, Ayechen" uniqKey="Chan A" first="Ayechen" last="Chan">Ayechen Chan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garven, Alexandra" sort="Garven, Alexandra" uniqKey="Garven A" first="Alexandra" last="Garven">Alexandra Garven</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Cynthia" sort="Chan, Cynthia" uniqKey="Chan C" first="Cynthia" last="Chan">Cynthia Chan</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Toth, Cory" sort="Toth, Cory" uniqKey="Toth C" first="Cory" last="Toth">Cory Toth</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Chemical senses</title>
<title level="j" type="abbreviated">Chem. senses</title>
<idno type="ISSN">0379-864X</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Chemical senses</title>
<title level="j" type="abbreviated">Chem. senses</title>
<idno type="ISSN">0379-864X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term>
<term>Neuralgia</term>
<term>Neuropathic pain</term>
<term>Neuropathy</term>
<term>Olfaction</term>
<term>Performance</term>
<term>Type 2 diabetes</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Névralgie</term>
<term>Douleur neuropathique</term>
<term>Performance</term>
<term>Olfaction</term>
<term>Diabète de type 2</term>
<term>Neuropathie</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Olfactory dysfunction in neurodegenerative conditions such as Parkinson's syndrome and Alzheimer's disease can hallmark disease onset. We hypothesized that patients with diabetes mellitus, a condition featuring peripheral and central neurodegeneration, would have decreased olfaction abilities. We examined participants with diabetic peripheral neuropathy, participants with diabetes without diabetic peripheral neuropathy, and control participants in blinded fashion using standardized Sniffin' Sticks. Diabetic peripheral neuropathy severity was quantified using the Utah Early Neuropathy Scale. Further subcategorization of diabetic peripheral neuropathy based on presence of neuropathic pain was performed with Douleur Neuropathique 4 Questionnaires. Participants with diabetes had decreased olfactory sensitivity, impaired olfactory discrimination abilities, and reduced odor identification skills when compared with controls. However, loss of olfaction ability was, at least partially, attributed to presence of neuropathic pain on subcategory assessment, although pain severity was not associated with dysfunction. Those participants with diabetes without diabetic peripheral neuropathy and those with diabetic peripheral neuropathy without neuropathic pain had similar olfactory function as controls in general. The presence of neuropathic pain, associated with limited attention and concentration, may explain at least a portion of the olfactory dysfunction witnessed in the diabetic patient population.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0379-864X</s0>
</fA01>
<fA02 i1="01"><s0>CHSED8</s0>
</fA02>
<fA03 i2="1"><s0>Chem. senses</s0>
</fA03>
<fA05><s2>38</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BRADY (Shauna)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LALLI (Paul)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MIDHA (Nisha)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHAN (Ayechen)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GARVEN (Alexandra)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CHAN (Cynthia)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>TOTH (Cory)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary</s1>
<s2>Calgary, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>497-507</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16455</s2>
<s5>354000503830910040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0217482</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Chemical senses</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Olfactory dysfunction in neurodegenerative conditions such as Parkinson's syndrome and Alzheimer's disease can hallmark disease onset. We hypothesized that patients with diabetes mellitus, a condition featuring peripheral and central neurodegeneration, would have decreased olfaction abilities. We examined participants with diabetic peripheral neuropathy, participants with diabetes without diabetic peripheral neuropathy, and control participants in blinded fashion using standardized Sniffin' Sticks. Diabetic peripheral neuropathy severity was quantified using the Utah Early Neuropathy Scale. Further subcategorization of diabetic peripheral neuropathy based on presence of neuropathic pain was performed with Douleur Neuropathique 4 Questionnaires. Participants with diabetes had decreased olfactory sensitivity, impaired olfactory discrimination abilities, and reduced odor identification skills when compared with controls. However, loss of olfaction ability was, at least partially, attributed to presence of neuropathic pain on subcategory assessment, although pain severity was not associated with dysfunction. Those participants with diabetes without diabetic peripheral neuropathy and those with diabetic peripheral neuropathy without neuropathic pain had similar olfactory function as controls in general. The presence of neuropathic pain, associated with limited attention and concentration, may explain at least a portion of the olfactory dysfunction witnessed in the diabetic patient population.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>770B05F</s0>
<s1>II</s1>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Névralgie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Neuralgia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Neuralgia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Douleur neuropathique</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Neuropathic pain</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Dolor neuropática</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Performance</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Performance</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Rendimiento</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Olfaction</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Olfaction</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Olfación</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Diabète de type 2</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Type 2 diabetes</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Diabetes de tipo 2</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Neuropathie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Neuropathy</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Neuropatía</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Perception</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Perception</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Percepción</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Endocrinopathie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Endocrinopathy</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Endocrinopatía</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie métabolique</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>203</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>FRANCIS 13-0217482 INIST</NO>
<ET>Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients</ET>
<AU>BRADY (Shauna); LALLI (Paul); MIDHA (Nisha); CHAN (Ayechen); GARVEN (Alexandra); CHAN (Cynthia); TOTH (Cory)</AU>
<AF>Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary/Calgary, AB/Canada (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Chemical senses; ISSN 0379-864X; Coden CHSED8; Royaume-Uni; Da. 2013; Vol. 38; No. 6; Pp. 497-507; Bibl. 1 p.1/4</SO>
<LA>Anglais</LA>
<EA>Olfactory dysfunction in neurodegenerative conditions such as Parkinson's syndrome and Alzheimer's disease can hallmark disease onset. We hypothesized that patients with diabetes mellitus, a condition featuring peripheral and central neurodegeneration, would have decreased olfaction abilities. We examined participants with diabetic peripheral neuropathy, participants with diabetes without diabetic peripheral neuropathy, and control participants in blinded fashion using standardized Sniffin' Sticks. Diabetic peripheral neuropathy severity was quantified using the Utah Early Neuropathy Scale. Further subcategorization of diabetic peripheral neuropathy based on presence of neuropathic pain was performed with Douleur Neuropathique 4 Questionnaires. Participants with diabetes had decreased olfactory sensitivity, impaired olfactory discrimination abilities, and reduced odor identification skills when compared with controls. However, loss of olfaction ability was, at least partially, attributed to presence of neuropathic pain on subcategory assessment, although pain severity was not associated with dysfunction. Those participants with diabetes without diabetic peripheral neuropathy and those with diabetic peripheral neuropathy without neuropathic pain had similar olfactory function as controls in general. The presence of neuropathic pain, associated with limited attention and concentration, may explain at least a portion of the olfactory dysfunction witnessed in the diabetic patient population.</EA>
<CC>770B05F</CC>
<FD>Névralgie; Douleur neuropathique; Performance; Olfaction; Diabète de type 2; Neuropathie; Homme</FD>
<FG>Pathologie du   système nerveux; Trouble neurologique; Perception; Endocrinopathie; Maladie métabolique</FG>
<ED>Neuralgia; Neuropathic pain; Performance; Olfaction; Type 2 diabetes; Neuropathy; Human</ED>
<EG>Nervous system diseases; Neurological disorder; Perception; Endocrinopathy; Metabolic diseases</EG>
<SD>Neuralgia; Dolor neuropática; Rendimiento; Olfación; Diabetes de tipo 2; Neuropatía; Hombre</SD>
<LO>INIST-16455.354000503830910040</LO>
<ID>13-0217482</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000139 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000139 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Francis:13-0217482
   |texte=   Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients

Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing in Diabetes Mellitus Patients

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri